1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia

被引：67

作者：

Anandan, Sampath-Kumar ^{[1
]}

Webb, Heather Kay ^{[1
]}

Chen, Dawn ^{[1
]}

Wang, Yi-Xin ^{[1
]}

Aavula, Basker R. ^{[1
]}

Cases, Sylvaine ^{[1
]}

Cheng, Ying ^{[1
]}

Do, Zung N. ^{[1
]}

Mehra, Upasana ^{[1
]}

Vinh Tran ^{[1
]}

Vincelette, Jon ^{[1
]}

Waszczuk, Joanna ^{[1
]}

White, Kathy ^{[1
]}

Wong, Kenneth R. ^{[1
]}

Zhang, Le-Ning ^{[1
]}

Jones, Paul D. ^{[2
,3
]}

Hammock, Bruce D. ^{[2
,3
]}

Patel, Dinesh V. ^{[1
]}

Whitcomb, Randall ^{[1
]}

MacIntyre, D. Euan ^{[1
]}

Sabry, James ^{[1
]}

Gless, Richard ^{[1
]}

机构：

[1] Arete Therapeut Inc, San Francisco, CA 94080 USA

[2] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA

[3] Univ Calif Davis, UCD Canc Ctr, Davis, CA 95616 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 03期

关键词：

sEH inhibitor; AR9281; Efficacy; DIO model; AngII hypertension model; Diabetes; EPOXYEICOSATRIENOIC ACIDS; INSULIN-RESISTANCE; 12-(3-ADAMANTAN-1-YL-UREIDO)DODECANOIC ACID; VASCULAR INFLAMMATION; BLOOD-PRESSURE; HIGHLY POTENT; PHARMACOKINETICS; METABOLISM; DISCOVERY; ATHEROSCLEROSIS;

D O I：

10.1016/j.bmcl.2010.12.042

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea 14a (AR9281), a potent and selective soluble epoxide hydrolase inhibitor, was recently tested in a phase 2a clinical setting for its effectiveness in reducing blood pressure and improving insulin resistance in pre-diabetic patients. In a mouse model of diet induced obesity, AR9281 attenuated the enhanced glucose excursion following an intraperitoneal glucose tolerance test. AR9281 also attenuated the increase in blood pressure in angiotensin-II-induced hypertension in rats. These effects were dose-dependent and well correlated with inhibition of the sEH activity in whole blood, consistent with a role of sEH in the observed pharmacology in rodents. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：983 / 988

页数：6

共 15 条

[11] (2S,4S)-1-[2-(1,1-Dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV
Yeh, Teng-Kuang
Tsai, Ting-Yueh
Hsu, Tsu
Cheng, Jai-Hong
Chen, Xin
Song, Jen-Shin
Shy, Horng-Shing
Chiou, Mei-Chun
Chien, Chia-Hui
Tseng, Ya-Ju
Huang, Chung-Yu
Yeh, Kai-Chia
Huang, Yu-Lin
Huang, Chih-Hsiang
Huang, Yu-Wen
Wang, Min-Hsien
Tang, Hung-Kuan
Chao, Yu-Sheng
Chen, Chiung-Tong
Jiaang, Weir-Torn
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (12) : 3596 - 3600
[12] Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM-833 [(R)-N-(pyridazin-3-yl)-4-(7-(trifluoromethyl)chroman-4-yl)piperazine-1-carboxamide] in rats: Potential for the treatment of inflammatory pain
Endo, Toshiya
Takeuchi, Takashi
Maehara, Shunsuke
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (02):
[13] Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E
Rowbottom, Martin W.
Faraoni, Raffaella
Chao, Qi
Campbell, Brian T.
Lai, Andiliy G.
Setti, Eduardo
Ezawa, Maiko
Sprankle, Kelly G.
Abraham, Sunny
Lan Tran
Struss, Brian
Gibney, Michael
Armstrong, Robert C.
Gunawardane, Ruwanthi N.
Nepomuceno, Ronald R.
Valenta, Ianina
Hua, Helen
Gardner, Michael F.
Cramer, Merry D.
Gitnick, Dana
Insko, Darren E.
Apuy, Julius L.
Jones-Bolin, Susan
Ghose, Arup K.
Herbertz, Torsten
Ator, Mark A.
Dorsey, Bruce D.
Ruggeri, Bruce
Williams, Michael
Bhagwat, Shripad
James, Joyce
Holladay, Mark W.
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (03) : 1082 - 1105
[14] Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
Vaswani, Rishi G.
Gehling, Victor S.
Dakin, Les A.
Cook, Andrew S.
Nasveschuk, Christopher G.
Duplessis, Martin
Iyer, Priyadarshini
Balasubramanian, Srividya
Zhao, Feng
Good, Andrew C.
Campbell, Robert
Lee, Christina
Cantone, Nico
Cummings, Richard T.
Normant, Emmanuel
Bellon, Steven F.
Albrecht, Brian K.
Harmange, Jean-Christophe
Trojer, Patrick
Audia, James E.
Zhang, Ying
Justin, Neil
Chen, Shuyang
Wilson, Jon R.
Gamblin, Steven J.
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (21) : 9928 - 9941
[15] 1-[3-aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-12′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-13,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa 10.1016/j.bmel.2006.02.069
Pinto, Donald J. P.
Orwat, Michael J.
Quan, Mimi L.
Han, Qi
Galemmo, Robert A., Jr.
Amparo, Eugene
Wells, Brian
Ellis, Christopher
He, Ming Y.
Alexander, Richard S.
Rossi, Karen A.
Smallwood, Angela
Wong, Pancras C.
Luettgen, Joseph M.
Rendina, Alan R.
Knabb, Robert M.
Mersinger, Lawrence
Kettner, Charles
Bal, Steven
He, Kan
Wexler, Ruth R.
Lam, Patrick Y. S.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (15) : 4141 - 4147

← 1 2 →